Table 2.
Demographic, clinical characteristics, combination drugs, and endpoint differences among three subsites
| Site 1 PUTH (n = 75) | Site 2 PUSH (n = 100) | Site 3 JST (n = 31) | P value | |
|---|---|---|---|---|
| Age | 64.53 ± 13.11 | 58.67 ± 10.14 | 61.07 ± 9.21 | 0.004* |
| Male (%) | 59 (78.67) | 79 (79) | 23 (74.19) | 0.844 |
| TIA (%) | 6 (8) | 0 | 0 | 0.005* |
| Hypertension (%) | 57 (76) | 72 (72) | 20 (64.52) | 0.483 |
| Diabetes (%) | 35 (46.67) | 40 (40) | 14 (45.16) | 0.659 |
| Smoking (%) | 24 (32) | 54 (54) | 17 (54.84) | 0.009* |
| Previous stroke (%) | 22 (29.33) | 27 (27) | 7 (22.58) | 0.775 |
| CHD (%) | 12 (16) | 16 (16) | 3 (9.68) | 0.662 |
| Intracranial artery stenosis (%) | 48 (64) | 81 (81) | 20 (64.52) | 0.026* |
| Extracranial artery stenosis (%) | 7 (9.33) | 14 (14) | 6 (19.35) | 0.355 |
| Severe cerebral arterial stenosis (%) | 32 (42.67) | 20 (20) | 0 | < 0.001* |
| CCB (%) | 45 (60) | 47 (47) | 14 (45.16) | 0.176 |
| PPI (%) | 5 (6.67) | 0 | 0 | 0.011* |
| β-blocker (%) | 7 (9.33) | 14 (14) | 0 | 0.076 |
| ACEI/ARB (%) | 21 (28) | 35 (35) | 5 (16.13) | 0.123 |
| In-hospital NIHSS | 3.30 ± 3.11 | 2.02 ± 1.66 | 1.35 ± 1.36 | < 0.001* |
| Discharge NIHSS | 1.70 ± 2.05 | 1.32 ± 1.07 | 1.06 ± 1.12 | 0.092 |
| Clopidogrel and aspirin (%) | 44 (58.67) | 66 (66) | 25 (80.65) | 0.360 |
| PRU | 199.11 ± 64.82 | 154.97 ± 57.65 | 141.40 ± 67.87 | < 0.001* |
| Modification (%) | 29 (38.67) | 8 (8) | 2 (6.45) | < 0.001* |
| Loss to follow-up (%) | 22 (29.33) | 2 (2) | 1 (3.23) | < 0.001* |
| Primary endpoint (%) | 9 (12) | 6 (6) | 2 (6.45) | < 0.001* |
| Secondary endpoint (%) | 1 (1.33) | 0 | 0 | 0.416 |
PUTH Peking University Third Hospital, PUSH Peking University Shougang Hospital, JST Beijing Jishuitan Hospital Hui Longguan Branch